A preventive care strategy to reduce moderate or severe acute kidney injury after major surgery (BigpAK-2); a multinational, randomised clinical trial

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • BigpAK-2 study group - (Autor:in)
  • Alexander Zarbock - , Westfälische Wilhelms-Universität Münster (Autor:in)
  • Marlies Ostermann - , Guy's and St Thomas' NHS Foundation Trust (Autor:in)
  • Lui Forni - , Royal Surrey County Hospital NHS Foundation Trust, University of Surrey (Autor:in)
  • Christian Bode - , Universität Bonn (Autor:in)
  • Lennart Wild - , Universität Bonn (Autor:in)
  • Christian Putensen - , Universität Bonn (Autor:in)
  • Diego Parise Roux - , Hospital Ramon y Cajal (Autor:in)
  • Elena Elías Martín - , Hospital Ramon y Cajal (Autor:in)
  • Christian Arndt - , Philipps-Universität Marburg (Autor:in)
  • Tim Rahmel - , Ruhr-Universität Bochum (Autor:in)
  • Silvia de Rosa - , Azienda Sanitaria Ulss 6 Vicenza, Università degli Studi di Trento (Autor:in)
  • Céline Monard - , Université de Lausanne, Hôpital Édouard Herriot (Autor:in)
  • Antoine G. Schneider - , Université de Lausanne (Autor:in)
  • Adam Glass - , Queen's University Belfast (Autor:in)
  • Mona Jung-König - , Universität Heidelberg (Autor:in)
  • Stefano Romagnoli - , Università degli Studi di Firenze, Azienda Ospedaliera Universitaria (AOU) Careggi (Autor:in)
  • James Gossage - , Guy's and St Thomas' NHS Foundation Trust (Autor:in)
  • Nuttha Lumlertgul - , Guy's and St Thomas' NHS Foundation Trust (Autor:in)
  • Jan Gerrit Haaker - , St. Franziskus-Hospital Münster (Autor:in)
  • Javier Ripollés-Melchor - , Universidad Complutense de Madrid (Autor:in)
  • Savino Spadaro - , Azienda Ospedaliero-Universitaria di Ferrara (Autor:in)
  • Antonio Siniscalchi - , IRCCS Azienda Ospedaliero-Universitaria di Bologna (Autor:in)
  • Emmanuel Futier - , CHU de Clermont-Ferrand (Autor:in)
  • Lucie Aupetitgendre - , CHU de Clermont-Ferrand (Autor:in)
  • Irene Romero Bhathal - , Hospital del Mar (Autor:in)
  • Raquel García Álvarez - , Hospital Universitario 12 de Octubre (Autor:in)
  • Alice Bernard - , Universitätsklinikum Tübingen (Autor:in)
  • Peter Rosenberger - , Universitätsklinikum Tübingen (Autor:in)
  • Carola Wempe - , Westfälische Wilhelms-Universität Münster (Autor:in)
  • Mahan Sadjadi - , Westfälische Wilhelms-Universität Münster (Autor:in)
  • Melanie Meersch - , Westfälische Wilhelms-Universität Münster (Autor:in)
  • Karen Fischhuber - , Westfälische Wilhelms-Universität Münster (Autor:in)
  • Rinaldo Bellomo - , University of Melbourne, Monash University (Autor:in)
  • John A. Kellum - , University of Pittsburgh (Autor:in)
  • Thilo von Groote - , Westfälische Wilhelms-Universität Münster (Autor:in)
  • Andreas Güldner - , Klinik und Poliklinik für Anästhesiologie und Intensivtherapie (Autor:in)
  • Martin Mirus - , Klinik und Poliklinik für Anästhesiologie und Intensivtherapie (Autor:in)
  • Peter M. Spieth - , Klinik und Poliklinik für Anästhesiologie und Intensivtherapie (Autor:in)
  • David Shaw - (Autor:in)
  • Ghent University
  • Clermont-Ferrand University Hospital
  • Universitätsklinikum Münster

Abstract

Background Acute kidney injury (AKI) is a common and important complication of major surgery, yet recommended preventive care is rarely administered. We used urinary biomarkers to identify patients at high risk of AKI and implemented a preventive care strategy to reduce AKI within 72 h after major surgery. Methods BigpAK-2 was a multicentre randomised clinical trial done in 34 hospitals in Europe. Patients (aged ≥18 years) undergoing major surgery at high risk for AKI identified by predefined clinical risk factors and tubular stress biomarkers were randomly assigned to usual care or a preventive care strategy as per recommendations by the Kidney Disease Improving Global Outcome guidelines: advanced hemodynamic monitoring, optimisation of volume status and haemodynamics, avoidance of nephrotoxic drugs and radiocontrast agents, and prevention of hyperglycaemia. The primary outcome was the occurrence of moderate or severe AKI within 72 h after surgery, assessed in the intention-to-treat population. Safety was assessed by comparing rates of adverse events between groups. This trial is registered with ClinicalTrials.gov , NCT04647396 . Findings From Nov 25, 2020, to June 21, 2024, 7873 patients were screened and 1180 (15·0%) were randomly assigned (589 [49·9%] to the intervention group and 591 [50·1%] to the control group). Among the 1176 patients available for the primary endpoint analysis, moderate or severe AKI occurred in 84 (14·4%) patients in the intervention group and in 131 (22·3%) patients in the control group (odds ratio 0·57 [95% CI 0·40–0·79; p=0·0002; number needed to treat 12 [7–33]). There were no differences in adverse events. The most common adverse events were atrial fibrillation (50 [8·8%] in the intervention group vs 56 (9·7%) in the control group), hemodynamically relevant arrhythmias (41 [7·2%] in the intervention group vs 50 [8·6%] in the control group), significant bleeding or haemorrhage (34 [6·0%] in the intervention group vs 31 [5·3%] in the control group), and unplanned return to the operating room (29 [5·1%] in the intervention vs 38 [6·5%] in the control group). Interpretation Among adults at high risk for AKI undergoing major surgery, a preventive care strategy consisting of supportive measures and avoidance of nephrotoxins significantly reduced the occurrence of moderate or severe AKI without increasing adverse events. Funding BioMérieux.

Details

OriginalspracheEnglisch
Seiten (von - bis)2782-2791
Seitenumfang10
FachzeitschriftThe Lancet
Jahrgang406
Ausgabenummer10521
PublikationsstatusVeröffentlicht - 13 Dez. 2025
Peer-Review-StatusJa

Externe IDs

PubMed 41242333
ORCID /0000-0001-8494-1403/work/203814275
ORCID /0000-0003-3953-3253/work/203814321

Schlagworte

ASJC Scopus Sachgebiete